基线68Ga-FAPI与18F-FDG PET/CT预测不可切除肝细胞癌患者接受PD-1抑制剂联合仑伐替尼治疗反应及临床结局的比较
这项前瞻性队列研究纳入22例不可切除肝细胞癌患者,比较基线68Ga-FAPI PET/CT与18F-FDG PET/CT对PD-1抑制剂联合仑伐替尼治疗反应和生存的预测价值。联合治疗客观缓解率为41%(9/22),50%患者获得持久临床获益,中位无进展生存期和总生存期分别为4.8个月和14.4个月。68Ga-FAPI体积参数(FTV、TLF)较高的患者持久临床获益更差、PFS和OS更短,且为独立预后因素;18F-FDG参数组间重叠。
要点
- 联合治疗客观缓解率41%(9/22),50%患者获持久临床获益。
- 高68Ga-FAPI肿瘤负荷(FTV>230.46 cm3或TLF>961.74)预测更短PFS和OS。
- 基线68Ga-FAPI PET/CT可能有助于联合治疗前筛选uHCC患者。
核心结论
- 基线68Ga-FAPI PET/CT体积参数可能是预测PD-1抑制剂联合仑伐替尼治疗的uHCC患者持久临床获益、PFS和OS的独立预后因素。
- 基线68Ga-FAPI PET/CT可能有助于联合治疗前uHCC患者筛选。
研究设计与样本
- 前瞻性队列研究,纳入22例接受基线18F-FDG和68Ga-FAPI PET/CT并随后开始PD-1抑制剂联合仑伐替尼治疗的uHCC患者。
- 测量基线PET/CT半定量指标:18F-FDG SUVmax、代谢肿瘤体积、总病变糖酵解、68Ga-FAPI SUVmax、68Ga-FAPI高摄取肿瘤体积(FTV)和总病变成纤维细胞活化蛋白表达(TLF)。
- 主要终点为治疗后持久或非持久临床获益,次要终点为无进展生存期(PFS)和总生存期(OS)。
主要发现
- 联合治疗客观缓解率为41%(9/22),50%患者获得持久临床获益,中位PFS和OS分别为4.8个月和14.4个月。
- 非持久临床获益患者的FTV和TLF显著高于持久临床获益患者,而18F-FDG参数组间重叠。
- 高68Ga-FAPI肿瘤负荷(FTV>230.46 cm3或TLF>961.74 SUVbody weight·cm3)预测更短PFS(4.0 vs 13.5个月,P=0.016)和更短OS(7.8个月 vs 未达到,P=0.030)。
- 高代谢肿瘤负荷(代谢肿瘤体积>206.80 cm3或总病变糖酵解>693.53 SUVbody weight·cm3)患者OS更短,但差异未达统计学显著(P=0.085)。
- 多因素分析中,高68Ga-FAPI肿瘤负荷(HR 3.88,95%CI 1.26-12.01,P=0.020)和大血管侵犯(HR 4.00,95%CI 1.06-15.14,P=0.039)独立预测更短PFS;高68Ga-FAPI肿瘤负荷(HR 5.92,95%CI 1.19-29.42,P=0.035)和骨转移(HR 5.88,95%CI 1.33-25.93,P=0.022)独立预测更短OS。
关键数值与推荐
- 高68Ga-FAPI肿瘤负荷定义为FTV>230.46 cm3或TLF>961.74 SUVbody weight·cm3。
- 高代谢肿瘤负荷定义为代谢肿瘤体积>206.80 cm3或总病变糖酵解>693.53 SUVbody weight·cm3。
临床怎么用
- 基线68Ga-FAPI PET/CT体积参数可能有助于在PD-1抑制剂联合仑伐替尼治疗前筛选uHCC患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein contributes to immunosuppression and resistance to immunotherapies. This study aimed to compare baseline 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT and 18F-FDG PET/CT in response and survival prediction in unresectable hepatocellular carcinoma (uHCC) patients treated with the combination of programmed cell death 1 (PD-1) inhibitor and lenvatinib. Methods: In this prospective cohort study, 22 patients with uHCC who underwent baseline 18F-FDG and 68Ga-FAPI PET/CT and soon began taking a combination of PD-1 inhibitor and lenvatinib were recruited. Semiquantitative indices of baseline PET/CT were measured as 18F-FDG SUVmax, metabolic tumor volume, total lesion glycolysis, 68Ga-FAPI SUVmax, 68Ga-FAPI-avid tumor volume (FTV), and total lesion fibroblast activation protein expression (TLF). The primary endpoint was durable or nondurable clinical benefit after treatment, and the secondary endpoints were progression-free survival (PFS) and overall survival (OS). Results: The overall response rate of the combination therapy was 41% (9/22). Fifty percent of patients had durable clinical benefit. Median PFS and OS were 4.8 and 14.4 mo, respectively. Patients with nondurable clinical benefit showed a significantly higher FTV and TLF than those with durable clinical benefit, whereas 18F-FDG parameters overlapped. A higher 68Ga-FAPI-avid tumor burden (FTV > 230.46 cm3 or TLF > 961.74 SUVbody weight⋅cm3) predicted both shorter PFS (4.0 vs. 13.5 mo, P = 0.016) and shorter OS (7.8 mo vs. not reached, P = 0.030). Patients with a higher metabolic tumor burden (metabolic tumor volume > 206.80 cm3 or total lesion glycolysis > 693.53 SUVbody weight⋅cm3) showed a shorter OS although the difference did not reach statistical significance (P = 0.085). In multivariate analysis, a higher 68Ga-FAPI-avid tumor burden (hazard ratio [HR], 3.88 [95% CI, 1.26-12.01]; P = 0.020) and macrovascular invasion (HR, 4.00 [95% CI, 1.06-15.14]; P = 0.039) independently predicted a shorter PFS, whereas a higher 68Ga-FAPI-avid tumor burden (HR, 5.92 [95% CI, 1.19-29.42]; P = 0.035) and bone metastases (HR, 5.88 [95% CI, 1.33-25.93]; P = 0.022) independently predicted a shorter OS. Conclusion: Volumetric indices on baseline 68Ga-FAPI PET/CT were potentially independent prognostic factors to predict durable clinical benefit, PFS, and OS in uHCC patients treated with a combination of PD-1 and lenvatinib. Baseline 68Ga-FAPI PET/CT may facilitate uHCC patient selection before combination therapy.
引用
- Wu M, Wang Y, Yang Q, et al. Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib. J Nucl Med. 2023. PMID: 37500263. doi:10.2967/jnumed.123.265712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。